MHRA warns of serious eye-related adverse events after Dupixent use
Pharmaceutical Technology
DECEMBER 7, 2022
GlobalData anticipates that this safety update will likely raise physician and regulator vigilance regarding long-term Dupixent use but is unlikely to impact overall prescribing patterns for the product. This will, however, likely trigger Dupixent’s competitors to look more closely at the safety of their products.
Let's personalize your content